Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
15670 | 629 | 37.0 | 77% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
1512 | 6953 | ONCOLYTIC VIRUS//VIROTHERAPY//CYTOSINE DEAMINASE |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CB1954 | Author keyword | 52 | 82% | 5% | 31 |
2 | ADEPT | Author keyword | 43 | 47% | 10% | 66 |
3 | ANTIBODY DIRECTED ENZYME PRODRUG THERAPY | Author keyword | 20 | 67% | 3% | 18 |
4 | NITROREDUCTASE | Author keyword | 16 | 27% | 8% | 51 |
5 | VDEPT | Author keyword | 10 | 58% | 2% | 11 |
6 | HUMAN BETA GLUCURONIDASE | Author keyword | 8 | 100% | 1% | 5 |
7 | GDEPT | Author keyword | 7 | 29% | 3% | 21 |
8 | ANTIBODY ENZYME CONJUGATE | Author keyword | 6 | 71% | 1% | 5 |
9 | ESCHERICHIA COLI NITROREDUCTASE | Author keyword | 6 | 71% | 1% | 5 |
10 | NITROAROMATIC PRODRUG | Author keyword | 6 | 100% | 1% | 4 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CB1954 | 52 | 82% | 5% | 31 | Search CB1954 | Search CB1954 |
2 | ADEPT | 43 | 47% | 10% | 66 | Search ADEPT | Search ADEPT |
3 | ANTIBODY DIRECTED ENZYME PRODRUG THERAPY | 20 | 67% | 3% | 18 | Search ANTIBODY+DIRECTED+ENZYME+PRODRUG+THERAPY | Search ANTIBODY+DIRECTED+ENZYME+PRODRUG+THERAPY |
4 | NITROREDUCTASE | 16 | 27% | 8% | 51 | Search NITROREDUCTASE | Search NITROREDUCTASE |
5 | VDEPT | 10 | 58% | 2% | 11 | Search VDEPT | Search VDEPT |
6 | HUMAN BETA GLUCURONIDASE | 8 | 100% | 1% | 5 | Search HUMAN+BETA+GLUCURONIDASE | Search HUMAN+BETA+GLUCURONIDASE |
7 | GDEPT | 7 | 29% | 3% | 21 | Search GDEPT | Search GDEPT |
8 | ANTIBODY ENZYME CONJUGATE | 6 | 71% | 1% | 5 | Search ANTIBODY+ENZYME+CONJUGATE | Search ANTIBODY+ENZYME+CONJUGATE |
9 | ESCHERICHIA COLI NITROREDUCTASE | 6 | 71% | 1% | 5 | Search ESCHERICHIA+COLI+NITROREDUCTASE | Search ESCHERICHIA+COLI+NITROREDUCTASE |
10 | NITROAROMATIC PRODRUG | 6 | 100% | 1% | 4 | Search NITROAROMATIC+PRODRUG | Search NITROAROMATIC+PRODRUG |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | 5 AZIRIDIN 1 YL 2 4 DINITROBENZAMIDE CB1954 | 77 | 82% | 7% | 45 |
2 | G AMIDASE CONJUGATE | 57 | 95% | 3% | 19 |
3 | CB 1954 | 44 | 71% | 6% | 36 |
4 | THERAPY ADEPT | 42 | 75% | 5% | 30 |
5 | ADEPT | 37 | 56% | 7% | 45 |
6 | B NITROREDUCTASE | 34 | 93% | 2% | 13 |
7 | ESCHERICHIA COLI NITROREDUCTASE | 31 | 42% | 9% | 57 |
8 | INTERSTRAND CROSSLINKING AGENT | 21 | 73% | 3% | 16 |
9 | CB1954 | 19 | 71% | 2% | 15 |
10 | 5 AZIRIDIN 1 YL 2 4 DINITROBENZAMIDE CB 1954 | 18 | 57% | 3% | 21 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Targeting: The ADEPT Story So Far | 2009 | 33 | 35 | 74% |
Antibody-directed enzyme prodrug therapy (ADEPT) for cancer | 2006 | 51 | 84 | 64% |
Beta-glucuronidase-mediated drug release | 2002 | 65 | 63 | 71% |
Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates | 2001 | 87 | 90 | 78% |
The choice of prodrugs for gene directed enzyme prodrug therapy of cancer | 1995 | 115 | 55 | 71% |
Antibody-enzyme conjugates for cancer therapy | 1996 | 75 | 67 | 69% |
Targeted Prodrug Approaches for Hormone Refractory Prostate Cancer | 2015 | 2 | 164 | 14% |
Antibody-directed enzyme prodrug therapy (ADEPT): A review | 1997 | 65 | 95 | 87% |
DESIGN OF ANTITUMOR PRODRUGS - SUBSTRATES FOR ANTIBODY-TARGETED ENZYMES | 1994 | 86 | 35 | 97% |
Antibody directed enzyme prodrug therapy (ADEPT): A review of the experimental and clinical considerations | 1999 | 82 | 56 | 61% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | TY MYDDFAI | 4 | 75% | 0.5% | 3 |
2 | ADUBILTEM SCI TECHNOL DEV | 3 | 100% | 0.5% | 3 |
3 | NUCL PLICAT | 3 | 14% | 3.2% | 20 |
4 | COBRA THER EUT LTD | 2 | 44% | 0.6% | 4 |
5 | MED KLIN WERPUNKT HAMATOL ONKOL CBF | 1 | 100% | 0.3% | 2 |
6 | GRP SYST MOL PROGRAMMES | 1 | 33% | 0.3% | 2 |
7 | CIBLAGE IMAGERIE FONCT PROG S TUMORALE | 1 | 50% | 0.2% | 1 |
8 | CLIN VACCINOL TROP MED NDM | 1 | 50% | 0.2% | 1 |
9 | CR UK TARGETING IMAGING GRP | 1 | 50% | 0.2% | 1 |
10 | IMMUNREGULAT | 1 | 50% | 0.2% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000158767 | DUOCARMYCINS//CC 1065//DUOCARMYCIN |
2 | 0.0000151040 | CYTOSINE DEAMINASE//SUICIDE GENE THERAPY//HERPES SIMPLEX VIRUS THYMIDINE KINASE |
3 | 0.0000136019 | SELF IMMOLATIVE//POLYMETHYL GLYOXYLATE//BIOMED SCI PROGRAMS |
4 | 0.0000130412 | CORTISOL METABOLITE//GLUCRONIDE//PHAMACOL THER EUT |
5 | 0.0000093380 | ANTIBODY DRUG CONJUGATE//ANTIBODY DRUG CONJUGATES//T DM1 |
6 | 0.0000090671 | BACTOFECTION//BACTERIAL THERAPY//SALMONELLA TYPHIMURIUM A1 R |
7 | 0.0000085067 | TIRAPAZAMINE//HYPOXIC CELL RADIOSENSITIZER//KU 2285 |
8 | 0.0000071736 | HPMA COPOLYMERS//HPMA COPOLYMER//POLYMER THER EUT |
9 | 0.0000068121 | GRP PEPTIDE CHEM//BRANCHED POLYPEPTIDES//HUNGARIAN SCI PEPTIDE CHEM GRP |
10 | 0.0000060466 | PROXIMITY ORIENTATION//CYCLIC PRODRUG//ESTERASE SENSITIVE PRODRUGS |